Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Heartburn drugs may increase the risk of stroke
NEW ORLEANS — Popular heartburn medication may increase the risk of ischemic stroke.
ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’)
MOUNTAIN VIEW, CA, USA I ChemoCentryx, Inc.
CRISPR gene-editing tested in a person for the first time
A Chinese group has become the first to inject a person with cells that contain genes edited using the revolutionary CRISPR–Cas9 technique.
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
Basel, 15 November 2016.
Myelofibrosis market will exceed $1 billion by 2025, says GlobalData
The myelofibrosis market is expected to almost double in value from $545.
FDA nod helps BMS' Opdivo even the head-and-neck cancer score with Merck's Keytruda
Thursday was quite the day for Bristol-Myers Squibb’s Opdivo.
Will Trump’s election make pharma M&A great again?
Good news, biopharma companies.
Haiti launches massive cholera vaccination drive but worries remain
Haiti has launched a massive cholera vaccination campaign to battle a flare-up after Hurricane Matthew, but concerns remain about the capacity for longer-term improvements to water and sanitation infr...
Valeant may seek to clean up its name by changing it: Ackman
Valeant Pharmaceuticals International Plc (VRX.
Mylan profit misses estimates as EpiPen sales decline
Mylan's third-quarter profit missed analysts' estimates as the drugmaker sold fewer EpiPen emergency allergy shots ahead of a cheaper version of the product that could be launched before next ...
AstraZeneca profit up 32% on year on tax gain
AstraZeneca PLC was boosted by a one-off tax windfall in the third quarter, helping offset heavy investment into the drugs it hopes will fuel strong growth.
Exclusive: Pfizer weighs sale or spin-off of consumer health unit - sources
U.
592
593
594
595
596
597
598
599
600
